OBJECTIVE: To evaluate treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer. METHODS: IL-2 1 x 10(5)-2 x 10(5) U per day was injected into tumor for 10 days; during the 4th-8th day LAK cells 1.0 x 10(8)-5.0 x 10(8) per day were combined with IL-2 injection. Then we analysized clinical effect, immunopathology, side effects, etc. RESULTS: CR was seen in 1 case; PR in 6, MR in 20 cases, and SD in 6 cases. The one-, two- and three-year survival rate was 96.3%, 83.3% or 75.0% respectively. The results of histopathology showed that there were large amount of T lymphocytes (CD3+/4+) infiltrating in the tumor area after immunotherapy. No serious side effects were found during the course of the treatment. CONCLUSION: Local injection of IL-2/LAK can be used as immunotherapy for head and neck cancer.
OBJECTIVE: To evaluate treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer. METHODS:IL-2 1 x 10(5)-2 x 10(5) U per day was injected into tumor for 10 days; during the 4th-8th day LAK cells 1.0 x 10(8)-5.0 x 10(8) per day were combined with IL-2 injection. Then we analysized clinical effect, immunopathology, side effects, etc. RESULTS:CR was seen in 1 case; PR in 6, MR in 20 cases, and SD in 6 cases. The one-, two- and three-year survival rate was 96.3%, 83.3% or 75.0% respectively. The results of histopathology showed that there were large amount of T lymphocytes (CD3+/4+) infiltrating in the tumor area after immunotherapy. No serious side effects were found during the course of the treatment. CONCLUSION: Local injection of IL-2/LAK can be used as immunotherapy for head and neck cancer.